- Home
- ABEO vs BWAY Comparison
ABEO vs BWAY Comparison
Compare ABEO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- BWAY
- Stock Information
- Founded
- ABEO 1974
- BWAY 2003
- Country
- ABEO United States
- BWAY Israel
- Employees
- ABEO N/A
- BWAY N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- BWAY Medical/Dental Instruments
- Sector
- ABEO Health Care
- BWAY Health Care
- Exchange
- ABEO Nasdaq
- BWAY Nasdaq
- Market Cap
- ABEO 281.0M
- BWAY 280.7M
- IPO Year
- ABEO 1980
- BWAY 2019
- Fundamental
- Price
- ABEO $4.36
- BWAY $16.17
- Analyst Decision
- ABEO Strong Buy
- BWAY Strong Buy
- Analyst Count
- ABEO 5
- BWAY 2
- Target Price
- ABEO $18.20
- BWAY $18.00
- AVG Volume (30 Days)
- ABEO 1.5M
- BWAY 66.3K
- Earning Date
- ABEO 11-13-2025
- BWAY 11-11-2025
- Dividend Yield
- ABEO N/A
- BWAY N/A
- EPS Growth
- ABEO N/A
- BWAY 679.98
- EPS
- ABEO 0.99
- BWAY 0.11
- Revenue
- ABEO $400,000.00
- BWAY $46,084,000.00
- Revenue This Year
- ABEO N/A
- BWAY $335.63
- Revenue Next Year
- ABEO $324.71
- BWAY $22.10
- P/E Ratio
- ABEO $4.41
- BWAY $58.29
- Revenue Growth
- ABEO N/A
- BWAY 26.50
- 52 Week Low
- ABEO $3.93
- BWAY $7.84
- 52 Week High
- ABEO $7.54
- BWAY $17.92
- Technical
- Relative Strength Index (RSI)
- ABEO 24.72
- BWAY 50.17
- Support Level
- ABEO $5.29
- BWAY $16.65
- Resistance Level
- ABEO $5.41
- BWAY $17.92
- Average True Range (ATR)
- ABEO 0.24
- BWAY 0.62
- MACD
- ABEO -0.08
- BWAY -0.02
- Stochastic Oscillator
- ABEO 3.49
- BWAY 31.64
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.